Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD) (CASL-AD-01)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by University Hospital, Bonn.
Recruitment status was:  Active, not recruiting
Federal Ministry of Health, Germany
Information provided by:
University Hospital, Bonn Identifier:
First received: February 15, 2008
Last updated: November 8, 2010
Last verified: July 2010
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

Condition Intervention
Alzheimer's Disease
Drug: Reminyl retard

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Resource links provided by NLM:

Further study details as provided by University Hospital, Bonn:

Primary Outcome Measures:
  • Cerebral perfusion [ Time Frame: baseline and after 12 weeks ]

Secondary Outcome Measures:
  • Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog) [ Time Frame: baseline, after 12 and 24 weeks ]
  • Alzheimer's Disease Functional Assessment and Change Scale (ADFACS) [ Time Frame: baseline, after 12 and 24 weeks ]
  • Neuropsychiatric Inventory (NPI) [ Time Frame: baseline, after 12 and 24 weeks ]
  • Mini-Mental-Status-Examination (MMSE) [ Time Frame: baseline, after 12 and 24 weeks ]

Estimated Enrollment: 30
Study Start Date: February 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CASL-MRI
Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
Drug: Reminyl retard
retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
  • Underwritten study consent
  • No treatment with acetylcholinesterase inhibitors
  • Mini-Mental-State Examination: 12-25 points
  • Age: 50-80 Years
  • Orale contraception for women of child-bearing age

Exclusion Criteria:

  • Mental Disorders
  • Other Diseases of the CNS
  • Severe Illness
  • Contraindication for MRI-Scan
  • Contraindication for Galantamin (Reminyl retard®)
  • Participation at other clinical trials
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00637442

Department of Psychiatry, University Bonn
Bonn, Germany, 53127
Sponsors and Collaborators
University Hospital, Bonn
Federal Ministry of Health, Germany
Principal Investigator: Frank Jessen, MD University Bonn
  More Information

Responsible Party: Frank Jessen, MD, University Hospital, Bonn Identifier: NCT00637442     History of Changes
Other Study ID Numbers: University Bonn
Study First Received: February 15, 2008
Last Updated: November 8, 2010

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents processed this record on May 25, 2017